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The present study was designed to examine the de-
velopment of hypertension in diabetic rats treated
with streptozotocin (STZ, lmg/g bw). The rats were
studied at 3, 6, 9, 12 and 15 weeks. From the third
week the rats were divided in diabetic rats according
their glycemias and controls, along 15 weeks. After
the third week a group of rats showed increased uri-
nary protein excretion (93, 134, 155 and 191%) com-
pared to controls. ,In this group of rats the urinary
kallikrein excretion was lower than control and the
systolic blood pressure became significantly elevated
between 3 and 6 weeks and persisted up to 15 weeks.
On the other hand a group of diabetic rats were nor-
motensive with urinary protein excretion similar to
controls and urinary kallikrein lower compared to
control but significantly higher compared diabetic
hypertensive rats. These data suggest that the associ-
ation of progressive diabetic nephropathy with ab-
normal endothelium-dependent vasodilation may
produce a high prevalence of hypertensive diabetes.
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INTRODUCTION
Renal kallikrein is a senine protease located in the
distal cortical nephron. Ill By its action on kinino-
gen substrate it generates potent vasoactive
kinins. Several observations link this enzyme and
its product to the regulation of hemodynamic
and ion transporting processes. Diabetes mellitus
and hypertension are common chronic conditions
which frequently coexist. According to Viberti
et a/. [2] the progression of diabetic nephropathy
appears to be closely related to blood pressure ele-
vation. Several studies show that the measure of
urinary protein loss correlates with the rate of
renal function deterioration. Early morphologic
lesions of diabetic nephropathy develop in practi-
cally all IDDM within a few years after the onset
of their metabolic abnormality.TM On the other
hand essential hypertension accounts for the
majority of cases of hypertension in the diabetic
population. Extensive evidence indicates an
association of kallikrein-kinin system with blood
pressure regulation. In the present study, we in-
vestigated whether the progressive increase of
proteinuria and the decreased urinary kallikrein
excretion may contribute to the hypertension in
the diabetic state.
MATERIALS AND METHODS
Neonatal male rats (2 days old) were used in his
study They were kept in a temperature con-
trolled environment with standard laboratory
food and water freely available. Diabetes was
induced by a single subcutaneous injection of
*Address for correspondence: Universidad Del Salvador. Fac. de Medicina. Cat. de Fisiologia. Tucuman 1845 CP 1050 Buenos
Aires, Argentina.
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streptozotocin (STZ), lmg/Kg bw dissolved in
citrate buffer (pH 4.5). Control rats of the same
age were injected with buffer alone. Blood sam-
ples were collected from the tail vein in subse-
quent periodic collections. Rats were housed two
to three per cage, and had access to water and
food ad libitum. Blood was collected from the tail
vein and urinary samples were collected housing
the animals in metabolic cages during 24h. Sys-
tolic blood pressure (SBP) was measured at dif-
ferent times with a pneumatic pulse transducer
and occluding tail cuff (Grass Mod. 79 Poligraph,
Grass Inst. Mass, USA). Rats were placed in re-
strainers at 28-30C and after lh, 4-6 determi-
nations of SBP were made and average.
Analytical Methods
Diabetes was confirmed by plasma glucose lev-
els measured after STZ injection and at 21, 42,
63, 85, 105 days. Urinary protein was measured
according to the procedure of Lowry et al. [41
and kallikrein was assayed as previously de-
scribed. Is] These parameters were measured over
a period of 15 weeks. Glomerular Filtration rate
(GFR) was measured according to Henry et al. [6]
Creatinine was measured with a Wiener kit
reagent (Wiener Arg. SA).
Chemicals
STZ was purchased from Sigma Chemical Co., St.
Louis, Mo. It was dissolved in 0.02M citrate
buffer, pH 4.5 and immediately injected intraperi-
toneal. The kallikrein assay was performed using
the synthetic chromogenic substrate H-D-Val-Leu-
Arg-pNA ($2266) from Kabi, Stockholm, Sweden.
The para-nitroanilide (pNA) released by enzy-
matic reaction on the substrate was measured
calorimetrically to determine kallikrein activity. [7]
Statistical Analysis
Data are expressed as mean +/-SEM. Differ-
ences were assessed by ANOVA. Intergroup
differences were analyzed by Student’s test for
unpaired data. Differences were considered
significant at a level of P < 0.05.
RESULTS
Three weeks after the initial STZ injection dia-
betic hypertensive rats (DH) showed signifi-
cantly lower body weight compared to control
rats. The average weight gain in DH rats
was 2.33+/-0.27 vs. 3.14+/-0.31g/day. No
differences were observed in diabetic normo-
tensive (DN) compared to controls. After the
15th weeks these differences persisted and the
average was 2.48+/-0.3 vs. 3.21+/-0.14g/
day. The kidney/body weight ratio also, was
significantly different at the 3rd and 15th weeks
in DH rats. GFR was observed significantly re-
duced in DH rats compared to controls (Tab. I).
When the diabetic and control rats were stud-
ied at different periods of time the following
results were obtained:
Blood glucose levels" Glucose steadily increased
in one group of diabetic animals over time from
TABLE Different parameters of the control and diabetic rats
3rd week
Control DN DH Control
15 weeks
DN DH
Body weight (g)
Kidney weight (g)
Kidney weight
Body weight ratio %
GF R ul/min
10 12 12 9 10 11
330+/-16 302+/- 10 245+/-17" 341+/-14 312+/-11 261+/-15"
3.2+/-0.02 2.8+/-0.5 2.9+/-0.4 3.1 +/-0.4 3.8+/-0.6 4.7+/-0.2*
0.97 +/-0.04 0.93 +/-0.03 1.18 +/-0.08* 0.90 +/-0.02 1.19 +/-0.04 1.88 +/-0.07*
0.37+/-0.05 0.50+/-0.04* 0.38+/-0.06 0.39+/-0.05 0.45+/-0.02 0.28+/-0.07*
DN: Diabetic Normotensive; DH: Diabetic Hypertensive.
Data are +/- DE *P<0.01 Diabetes vs. Control.
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the 3rd week to 15th weeks(30, 48, 47, 46 and
49% respectively). On the other hand other
group of diabetic rats showed 8, 25, 30 and 30%
increased blood glucose over time (Fig. 1).
Urinary protein excretion: Urinary protein ex-
cretion was observed progressively increased
over time in one group of diabetic rats (93, 134,
155, 199% DH) started from the 3rd week. In the
DN rats the increase of urinary protein secretion
was 25, 45, 50 and 57 from the 6th week (Fig. 2).
Total Kallikrein excretion: Kallikrein excretion
was observed progressively decreased in DH
rats from the 3rd to 15th weeks compared to
controls. However in DN rats the urinary
kallikrein excretion was significantly different
from the 6th week compared to control (Fig. 3).
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FIGURE 3 Urinary kallikrein excretion 0 Nr. of rats. Re-
sults are expressed as mean +/-SD. ANOVA was per-
formed to evaluate differences between groups. *P>0.05
Control vs. DH and DN.
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FIGURE 1 Blood glucose levels (mg%) in control, Diabetic
Normotensive (DN) and Diabetic Hypertensive (DH). ()
number of rats per groups. Mean +/-SEM, *P<0.05;
**P < 0.01.
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FIGURE 4 Systolic blood pressure in Control, Diabetic Nor-
motensive (DN) and Diabetic Hypertensive (DH). 0 number
of rats. Mean +/- SEM *P< 0.01.
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FIGURE 2 Urinary protein excretion in Control, Diabetic
Normotensives (DN) and Diabetic Hypertensives (DH) rats.
Mean +/- SEM *P< 0.01.
Systolic blood pressure: SBP was studied in
controls, DH and DN. In the DH rats the SBP
was significantly increased along the experiment
compared to controls rats (13, 18, 21, 27 and 32%
respectively). On the other hand diabetic rats
with moderated proteinuria and low kallikrein
after the 6th week showed no significant differ-
ences of SBP vs. control rats (Fig. 4).
DISCUSSION
The present study has clearly shown that in-
creased urinary protein excretion and lower
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kallikrein secretion is, probably one of the
possible mechanisms to produce diabetic hyper-
tension. Marre et al. I81 suggested that micro-
albuminuria in some hypertensive NIDDM
patients can be explained by the association
between essential hypertension and NIDDM.
Diagnosis of clinical nephropathy, however, is
made by the appearance of persistent protein-
uria which inaugurates a phase leading to an
end-stage renal disease (ESDR). Thus hyperten-
sion is often associated with diabetic nephro-
pathy. I91 Ours study examine the mechanisms
responsible for the abnormalities in the renal
function associated with the diabetic hyperten-
sion. We found that diabetes can produce some
changes in the progressive increase of urinary
protein excretion and reduced kallikrein secre-
tion when blood glucose is persistently higher
over time. Even though other mechanisms may
contribute to reduce tubuloglomerular feedback
and hyperfiltration in diabetes mellitus, stimula-
tion of cotransporter by hSGK is likely to
participate in the generation of diabetic hyper-
filtration. Beyond that, stimulation of epithelial
Na+ channel and cotransporter is expected to in-
duce Na+ retention and thus favour the develop-
ment of diabetic hypertensive disease.I11 In Fact,
the prevalence of hypertension in this case cor-
relates with the renal functional abnormalities
and the duration of diabetes. I11 According to
Christlieb [12] essential hypertension accounts for
the majority of cases of hypertension in the
diabetic population, and the pathogenesis of es-
sential hypertension in diabetic patients is con-
sidered to be similar to that in non diabetic
patients.I31 Furthermore an study by Knowler
et al. [14] on Pima Indians showed that prediabetic
elevated blood pressure occurred at higher rate
(36%) in those patients with increased protein-
uria and nephropathy than those with low or
without proteinuria and nephropathy (12%) In-
terestingly diabetic rats with moderate hyper-
glycemia, low proteinuria and low kallikrein
from the 9th week did not develop hyperten-
sion. The mechanisms trough which urinary
protein excretion did not rise and kallikrein ex-
cretion was low in this group of DN rats is not
completely clear. Previous studies have indicate
that diabetic patients in poor control of their
prior glycemias (HbA lc 11%) had 177% of uri-
nary protein excretion compared to controls,
whereas diabetic patients with HbA lc 11%
showed less of 100% of urinary protein excre-
tion. These results showed also that kallikrein
secretion rate was correlated with the HbA lc
level. [151 The magnitude of the diabetes state pro-
duces an impairment of rat renal kallikrein syn-
thesis with a decreased renal tissue and urinary
kallikrein secretion as it was demonstrated by
Jaffa et al. [16l in diabetic rats. On the other hand
insulin treatment increased kallikrein mRNA
levels, suggesting that diabetes suppresses
kallikrein gene expression. Severely hyper-
glycemic diabetic rats with normal GFR had
lower renal excretion of active kallikrein than
control animals, whereas moderately hyper-
glycemia diabetic rats exhibited higher urinary
levels of the enzyme.I51 According with our
results in the group of rats with diabetic
nephropathy the proteinuria was significant in-
creased over the time with a correlation with
decreased kallikrein. Taken together the data
suggest that there is a defect in the expression
and transcription of kallikrein in the diabetic
kidney as it was postulated in diabetic rats by
Jaffa et al. [16] Diabetic nephropathy produces
structural abnormalities as hypertrophy of
kidney, increase in the thickness of glomerular
basement membranes, accumulation of extracel-
lular matriz in the glomerulus, tubular atrophy
and interticial fibrosis. [17] It is relevant to point
out that functional alterations of diabetic
nephropathy produces an early proteinuria and
systemic hypertension. II81 In this regard, in hu-
man and animal diabetic models TGF-beta
mRNA and protein levels are significantly in-
creased in the glomeruli and tubulointersti-
cium. [171 On the other hand the deleterious effect
of proteinuria on the progression of renal dis-
ease may be mediated via TGF-beta. I191 The
suggestion that severely hyperglycemic diabetic
rats with increased proteinuria and low
kallikrein secretion shows hypertension is fur-
ther supported by studies that shows that
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endothelium function is abnormal in diabetic
rats.I21 In conclusion, the present study has
found that in long-term experimental diabetes
the progressive increase of urinary protein secre-
tion in the early state of diabetes and low
kallikrein excretion is one of the major pathways
responsible of diabetic hypertension.
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